<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26896473</article-id><article-id pub-id-type="pmc">4802470</article-id><article-id pub-id-type="doi">10.1161/JAHA.115.002762</article-id><article-id pub-id-type="publisher-id">JAH31337</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Vascular Medicine</subject></subj-group></subj-group></article-categories><title-group><article-title>Tetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis</article-title><alt-title alt-title-type="left-running-head">M&#x000e4;ki&#x02010;Pet&#x000e4;j&#x000e4; et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah31337-cr-0001" contrib-type="author" corresp="yes"><name><surname>M&#x000e4;ki&#x02010;Pet&#x000e4;j&#x000e4;</surname><given-names>Kaisa M.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31337-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31337-cr-0002" contrib-type="author"><name><surname>Day</surname><given-names>Lisa</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="jah31337-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="jah31337-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="jah31337-cr-0003" contrib-type="author"><name><surname>Cheriyan</surname><given-names>Joseph</given-names></name><degrees>MA, FRCP</degrees><xref ref-type="aff" rid="jah31337-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31337-cr-0004" contrib-type="author"><name><surname>Hall</surname><given-names>Frances C.</given-names></name><degrees>FRCP, DPhil</degrees><xref ref-type="aff" rid="jah31337-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31337-cr-0005" contrib-type="author"><name><surname>&#x000d6;st&#x000f6;r</surname><given-names>Andrew J. K.</given-names></name><degrees>MBBS, FRACP</degrees><xref ref-type="aff" rid="jah31337-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31337-cr-0006" contrib-type="author"><name><surname>Shenker</surname><given-names>Nicholas</given-names></name><degrees>FRCP, PhD</degrees><xref ref-type="aff" rid="jah31337-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31337-cr-0007" contrib-type="author"><name><surname>Wilkinson</surname><given-names>Ian B.</given-names></name><degrees>FRCP, DM</degrees><xref ref-type="aff" rid="jah31337-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jah31337-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Division of Experimental Medicine and Immunotherapeutics</named-content><named-content content-type="organisation-division">Addenbrooke's Hospital</named-content><institution>University of Cambridge</institution><country country="GB">UK</country></aff><aff id="jah31337-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Rheumatology Research Unit</named-content><named-content content-type="organisation-division">Addenbrooke's Hospital</named-content><institution>University of Cambridge</institution><country country="GB">UK</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Kaisa M. M&#x000e4;ki&#x02010;Pet&#x000e4;j&#x000e4;, PhD, Division of Experimental Medicine and Immunotherapeutics, Addenbrooke's Hospital, University of Cambridge, BOX 98, Cambridge CB2 0QQ, UK. E&#x02010;mail: <email>km391@medschl.cam.ac.uk</email></corresp><fn id="jah31337-note-0001"><label>&#x02020;</label><p>Deceased.</p></fn></author-notes><pub-date pub-type="epub"><day>19</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2016</year></pub-date><volume>5</volume><issue>2</issue><issue-id pub-id-type="doi">10.1002/jah3.2016.5.issue-2</issue-id><elocation-id>e002762</elocation-id><history><date date-type="received"><day>18</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-5-e002762.pdf"/><abstract id="jah31337-abs-0001"><sec id="jah31337-sec-0001"><title>Background</title><p>Rheumatoid arthritis is a systemic inflammatory condition associated with increased cardiovascular risk that may be due to underlying endothelial dysfunction and subsequent aortic stiffening. We hypothesized that supplementation with tetrahydrobiopterin (<styled-content style="fixed-case">BH</styled-content>
<sub>4</sub>) would recouple endothelial nitric oxide synthase and thus improve endothelial function and consequently reduce aortic stiffness.</p></sec><sec id="jah31337-sec-0002"><title>Methods and Results</title><p>We conducted 2 randomized, double&#x02010;blinded, placebo&#x02010;controlled crossover studies examining 2 separate regimens: an acute regimen, with a single dose of <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> 400&#x000a0;mg versus placebo (n=18), and a short&#x02010;term regimen, composed of a 1&#x02010;week treatment with <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> 400&#x000a0;mg once daily versus placebo (n=15). Flow&#x02010;mediated dilatation and aortic pulse wave velocity were studied 4 times, before and after each treatment phase. Acute <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> supplementation led to an improvement of flow&#x02010;mediated dilatation, whereas placebo had no effect (mean&#x000b1;<styled-content style="fixed-case">SD</styled-content> of effect difference 2.56&#x000b1;4.79%; <italic>P</italic>=0.03). Similarly, 1&#x02010;week treatment with <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> improved endothelial function, but there was no change with placebo (mean&#x000b1;<styled-content style="fixed-case">SD</styled-content> of effect difference 3.50&#x000b1;5.05%; <italic>P</italic>=0.02). There was no change in aortic pulse wave velocity following acute or short&#x02010;term <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> supplementation or placebo (mean&#x000b1;<styled-content style="fixed-case">SD</styled-content> of effect difference: acute 0.09&#x000b1;0.67&#x000a0;m/s, <italic>P</italic>=0.6; short&#x02010;term 0.03&#x000b1;1.46&#x000a0;m/s, <italic>P</italic>=0.9).</p></sec><sec id="jah31337-sec-0003"><title>Conclusion</title><p>Both acute and short&#x02010;term supplementation with oral <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> improved endothelial function but not aortic stiffness. This result suggests that <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> supplementation may be beneficial for patients with rheumatoid arthritis by improving endothelial dysfunction and potentially reducing risk of cardiovascular disease. There appears to be no causal relationship between endothelial function and aortic stiffness, suggesting that they occur in parallel, although they may share common risk factors such as inflammation.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah31337-kwd-0001">arteriosclerosis</kwd><kwd id="jah31337-kwd-0002">endothelial function</kwd><kwd id="jah31337-kwd-0003">inflammation</kwd><kwd id="jah31337-kwd-0004">rheumatoid arthritis</kwd><kwd id="jah31337-kwd-0005">tetrahydrobiopterin</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Endothelium/Vascular Type/Nitric Oxide</kwd><kwd>Inflammation</kwd><kwd>Oxidant Stress</kwd></kwd-group><funding-group><award-group><funding-source>British Heart Foundation</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Comprehensive Local Research Network</funding-source></award-group></funding-group><funding-group><award-group><funding-source>National Institute for Health Research</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Cambridge Biomedical Research Centre</funding-source></award-group></funding-group><counts><page-count count="9"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah31337</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.4 mode:remove_FC converted:03.03.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah31337-cit-1001">(<source>J Am Heart Assoc</source>. <year>2016</year>;<volume>5</volume>:e002762 doi: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.115.002762">10.1161/JAHA.115.002762</ext-link>)</mixed-citation>
</p></notes></front><body><sec id="jah31337-sec-0004"><title>Introduction</title><p>Rheumatoid arthritis (RA) and other chronic inflammatory diseases are associated with increased premature mortality, mostly due to an excess of cardiovascular disease (CVD).<xref rid="jah31337-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31337-bib-0002" ref-type="ref">2</xref> A number of underlying mechanisms have been proposed, including endothelial dysfunction. Reduced nitric oxide (NO) bioavailability or endothelial dysfunction is thought to be a key early step in the initiation of atherosclerosis and predicts future CVD&#x02010;related events in a variety of populations, improving risk classification beyond the Framingham Heart Study scores.<xref rid="jah31337-bib-0003" ref-type="ref">3</xref>, <xref rid="jah31337-bib-0004" ref-type="ref">4</xref> We and others have demonstrated that RA patients have endothelial dysfunction,<xref rid="jah31337-bib-0005" ref-type="ref">5</xref>, <xref rid="jah31337-bib-0006" ref-type="ref">6</xref>, <xref rid="jah31337-bib-0007" ref-type="ref">7</xref>, <xref rid="jah31337-bib-0008" ref-type="ref">8</xref>, <xref rid="jah31337-bib-0009" ref-type="ref">9</xref> which can be improved with anti&#x02010;inflammatory therapies.<xref rid="jah31337-bib-0010" ref-type="ref">10</xref>, <xref rid="jah31337-bib-0011" ref-type="ref">11</xref>, <xref rid="jah31337-bib-0012" ref-type="ref">12</xref> Aortic stiffening, an independent risk factor for CVD,<xref rid="jah31337-bib-0013" ref-type="ref">13</xref> has also been implicated. Several groups have reported increased aortic pulse wave velocity (aPWV) in RA and suggested that this could be a consequence of endothelial dysfunction.<xref rid="jah31337-bib-0010" ref-type="ref">10</xref>, <xref rid="jah31337-bib-0014" ref-type="ref">14</xref>, <xref rid="jah31337-bib-0015" ref-type="ref">15</xref>, <xref rid="jah31337-bib-0016" ref-type="ref">16</xref> Previous studies suggested a link between endothelial function and stiffness of muscular arteries,<xref rid="jah31337-bib-0017" ref-type="ref">17</xref>, <xref rid="jah31337-bib-0018" ref-type="ref">18</xref> but whether endothelial function is causally related to aortic stiffness is unknown.</p><p>The mechanism of endothelial dysfunction in RA is incompletely understood, but reduced tetrahydrobiopterin (<styled-content style="fixed-case">BH</styled-content>
<sub>4</sub>) availability or stability<xref rid="jah31337-bib-0019" ref-type="ref">19</xref> and increased production of reactive oxygen species have been suggested.<xref rid="jah31337-bib-0020" ref-type="ref">20</xref> Under basal conditions, endothelial nitric oxide synthase (eNOS) is responsible for NO production, but during inflammation, inducible NOS is also expressed in arterial endothelial cells. Inducible NOS activation impairs vasorelaxation in&#x000a0;vitro, at least in part, by limiting availability of BH<sub>4</sub> to eNOS,<xref rid="jah31337-bib-0021" ref-type="ref">21</xref> and we have demonstrated in&#x000a0;vivo that inducible NOS activation in RA is independently related to endothelial function.<xref rid="jah31337-bib-0009" ref-type="ref">9</xref> BH<sub>4</sub> deficiency is thought to lead to eNOS uncoupling, in which electrons flowing from the reductase domain to the oxygenase domain are diverted to molecular oxygen rather than <sc>l</sc>&#x02010;arginine, leading to production of superoxide (O<sub>2</sub>
<sup>&#x02212;</sup>) rather than NO.<xref rid="jah31337-bib-0022" ref-type="ref">22</xref> Increased release of myeloperoxidase from activated neutrophils may also play an important role in endothelial dysfunction in RA. Myeloperoxidase catalytically consumes NO and increases the production of reactive oxygen species, subsequently leading to uncoupling of eNOS<xref rid="jah31337-bib-0020" ref-type="ref">20</xref> and oxidation of BH<sub>4</sub> to inactive BH<sub>2.</sub>
<xref rid="jah31337-bib-0019" ref-type="ref">19</xref>, <xref rid="jah31337-bib-0023" ref-type="ref">23</xref>, <xref rid="jah31337-bib-0024" ref-type="ref">24</xref> We and others have shown that circulating myeloperoxidase levels are elevated in patients with RA<xref rid="jah31337-bib-0009" ref-type="ref">9</xref>, <xref rid="jah31337-bib-0025" ref-type="ref">25</xref> and independently predict endothelial dysfunction in patients with unstable coronary disease<xref rid="jah31337-bib-0026" ref-type="ref">26</xref> and RA.<xref rid="jah31337-bib-0009" ref-type="ref">9</xref> Inflammation appears to reduce BH<sub>4</sub> bioavailability, which may in part mediate the endothelial dysfunction present in RA; therefore, supplementation with BH<sub>4</sub> may be a reasonable therapeutic option to restore normal eNOS function and thus endothelial function in RA. Previous studies have demonstrated that intra&#x02010;arterial administration of BH<sub>4</sub> improves endothelium&#x02010;dependent dilation in patients with hypercholesterolemia,<xref rid="jah31337-bib-0027" ref-type="ref">27</xref> coronary artery disease,<xref rid="jah31337-bib-0028" ref-type="ref">28</xref> and type II diabetes.<xref rid="jah31337-bib-0029" ref-type="ref">29</xref> Oral BH<sub>4</sub> supplementation improves endothelial function in elderly participants,<xref rid="jah31337-bib-0030" ref-type="ref">30</xref> in long&#x02010;term smokers,<xref rid="jah31337-bib-0031" ref-type="ref">31</xref> and in patients with hypercholesterolemia<xref rid="jah31337-bib-0032" ref-type="ref">32</xref> and hypertension.<xref rid="jah31337-bib-0033" ref-type="ref">33</xref> No studies to date, however, have investigated the effects of BH<sub>4</sub> in patients with RA. Moreover, it is unclear if improvement of endothelial function would lead to a reduction of aortic stiffness or if other mechanisms are responsible for increased aortic stiffness.</p><p>Our aim was to test the hypotheses (1) that oral BH<sub>4</sub> supplementation would improve endothelial function in patients with RA and (2) that an improvement of endothelial function would lead to subsequent amelioration of aortic stiffening, providing evidence about the causal relationship between endothelial function and aortic stiffness; BH<sub>4</sub> is thought to have little direct effect on inflammation per se.</p></sec><sec id="jah31337-sec-0005"><title>Methods</title><sec id="jah31337-sec-0006"><title>Study Population</title><p>Overall, 33 patients with active RA (disease activity score [DAS28] &#x0003e;3.5) who met the 1987 American Rheumatism Association criteria were recruited from the rheumatology clinics at Addenbrooke's Hospital, Cambridge, United Kingdom. Patients with manifest CVD, untreated hypertension (blood pressure &#x02265;140/90&#x000a0;mm&#x000a0;Hg), diabetes, hypercholesterolemia (total cholesterol &#x02265;6.5&#x000a0;mmol/L), or renal disease and current smokers were excluded because these conditions are associated with endothelial dysfunction and arterial stiffening.<xref rid="jah31337-bib-0034" ref-type="ref">34</xref> To determine whether baseline endothelial function and aortic stiffness were abnormal in RA patients, 33 age&#x02010; and sex&#x02010;matched healthy control participants were randomly selected from our database to compare baseline endothelial function and aortic stiffness. A favorable ethics opinion was obtained from the National Research Ethics Service, and written informed consent was obtained from each participant prior any study procedures.</p></sec><sec id="jah31337-sec-0007"><title>Pilot Proof&#x02010;of&#x02010;Concept Study</title><p>We conducted a small pilot study in 5 healthy nonsmoking control participants (mean age 27&#x000b1;6&#x000a0;years) to test whether a single dose of BH<sub>4</sub> 400&#x000a0;mg would improve endothelial function. We found that flow&#x02010;mediated dilatation (FMD) response increased (from 5.79&#x000b1;1.77% to 11.37&#x000b1;4.05%; <italic>P</italic>=0.009), and there was a significant change in the baseline diameter (from 3.77&#x000b1;.52 to 4.10&#x000b1;0.62&#x000a0;mm; <italic>P</italic>=0.008); however, there was no change in mean arterial pressure (<italic>P</italic>=0.1) or aPWV (<italic>P</italic>=0.2). Data are presented as mean&#x000b1;SD, and significance was determined using the paired Student <italic>t</italic> test. Based on these pilot data, the 400&#x000a0;mg once&#x02010;daily dose was deemed sufficient for the main study in RA patients and was similar to doses used previously in other conditions.<xref rid="jah31337-bib-0019" ref-type="ref">19</xref>, <xref rid="jah31337-bib-0033" ref-type="ref">33</xref>
</p></sec><sec id="jah31337-sec-0008"><title>Experimental Protocol</title><p>The present study was conducted in a randomized, double&#x02010;blind, crossover manner. To determine whether acute changes were sustained, patients were allocated to 1 of 2 groups: acute or short&#x02010;term BH<sub>4</sub> supplementation.</p><p>In the acute study, participants made two 6&#x02010;hour visits to the vascular laboratory (Figure&#x000a0;<xref rid="jah31337-fig-0001" ref-type="fig">1</xref>A). On day 1, following the baseline measurement of endothelial function, aortic stiffness, DAS28, and venous blood sampling, participants received a single oral dose of BH<sub>4</sub> 400&#x000a0;mg or placebo (random assignment). At 3 hours after the administration of BH<sub>4</sub> or placebo, the hemodynamic measurements were repeated. A 3&#x02010;hour time point was chosen based on published pharmacokinetic data.<xref rid="jah31337-bib-0035" ref-type="ref">35</xref> One week later, the same protocol was followed, and participants again received either BH<sub>4</sub> or placebo.</p><fig fig-type="Figure" xml:lang="en" id="jah31337-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Schema of the study design. A, All participants made 2 visits, separated by 1&#x000a0;week. At each time point, blood pressure, arterial stiffness, and endothelial function were assessed, and a blood sample was taken. B, All participants made 4 visits to the unit on days 0, 7, 14, and 21. At each visit, blood pressure, arterial stiffness, endothelial function, and disease activity were assessed, and a blood sample was taken. <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> indicates tetrahydrobiopterin.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-5-e002762-g001"/></fig><p>In the short&#x02010;term supplementation study, participants made 4 visits, each separated by 1 week. Participants received BH<sub>4</sub> 400&#x000a0;mg once daily or placebo (random order), each for 1&#x000a0;week, with 1&#x02010;week washout between treatments (Figure&#x000a0;<xref rid="jah31337-fig-0001" ref-type="fig">1</xref>B). All hemodynamic measurements were assessed at baseline and at the end of each 7&#x02010;day treatment period (treatment 1, washout, and treatment 2). Blood was drawn at each time point for the measurement of biochemical markers, and DAS28 was calculated.</p></sec><sec id="jah31337-sec-0009"><title>BH<sub>4</sub> Tablets</title><p>BH<sub>4</sub> was given in a form of sapropterin dihydrochloride (6R&#x02010;BH<sub>4</sub>). 6R&#x02010;BH<sub>4</sub> is the synthetic form of naturally occurring BH<sub>4</sub> (BioMarin Pharmaceutical Inc) and is approved for treatment of BH<sub>4</sub>&#x02010;responsive phenylketonuria.</p></sec><sec id="jah31337-sec-0010"><title>Hemodynamic Measurements</title><p>All studies were conducted in a quiet, temperature&#x02010;controlled room. Blood pressure was recorded in the brachial artery using a validated oscillometric technique (HEM&#x02010;705CP; Omron Corp). Radial artery waveforms were obtained with a high&#x02010;fidelity micromanometer (SPC&#x02010;301; Millar Instruments) from the wrist, and a corresponding central waveform was generated using a validated transfer function (Sphygmocor; AtCor Medical). Augmentation index (AIx), a composite measure of wave reflection, mean arterial pressure and heart rate were determined using the integrated software. Aortic and brachial pulse wave velocities were measured, as previously described.<xref rid="jah31337-bib-0036" ref-type="ref">36</xref>
</p><p>Endothelial function was assessed in the brachial artery using the FMD technique.<xref rid="jah31337-bib-0037" ref-type="ref">37</xref> Vessel diameter was measured using high&#x02010;resolution vascular ultrasound (Acuson Aspen; Siemens AG) with a 10.0&#x02010;MHz linear&#x02010;array transducer. Brachial artery diameter was measured continuously for 1&#x000a0;minute at baseline and for a further 5&#x000a0;minutes following cuff deflation. The cuff was placed below (distal to) the ultrasound transducer and inflated to 200&#x000a0;mm&#x000a0;Hg for 5&#x000a0;minutes. After return to baseline, vessel diameter was again measured continuously for 5&#x000a0;minutes following administration of 25&#x000a0;&#x003bc;g of sublingual glyceryl trinitrate. FMD was defined as the maximum percentage increase in vessel diameter during reactive hyperemia; glyceryl trinitrate&#x02013;mediated dilatation was defined as the maximum percentage increase in vessel diameter after sublingual glyceryl trinitrate. FMD recordings were analyzed offline by a blinded operator using Cardiovascular Suite Software (Quipu).</p></sec><sec id="jah31337-sec-0011"><title>Laboratory Measurements and DAS28</title><p>Fasting lipid profile, high&#x02010;sensitivity C&#x02010;reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were determined using standard methodology at the Biochemistry Laboratory at Addenbrooke's Hospital.</p><p>DAS28 is a validated composite disease activity score. The components of DAS28 include the number of swollen and tender joints from 28 assessed joints, ESR, and patient&#x02010;assessed visual analog score of overall well&#x02010;being (scale 0&#x02013;100). DAS28 was calculated as described previously.<xref rid="jah31337-bib-0038" ref-type="ref">38</xref>
</p></sec><sec id="jah31337-sec-0012"><title>Data Analysis</title><p>The primary outcome of the study was the difference in FMD response between BH<sub>4</sub> and placebo treatments. Secondary outcomes were differences in aPWV between treatments, the relationship between changes in aPWV and FMD, and the relationship between CRP and disease activity and change in FMD and aPWV.</p><p>Based on our pilot data and published data on BH<sub>4</sub> supplementation, we calculated that a total of 15 patients (per study) were needed to enter the 2&#x02010;treatment crossover study to provide &#x0003e;80% power at <italic>P</italic>&#x0003c;0.05 to detect a 4.0&#x02010;U difference in FMD response between treatments with an SD of 5.0. Data were analyzed using SPSS software (version 21.0; IBM Corp). Two&#x02010;way repeated&#x02010;measures ANOVA was used to investigate the effect of the treatment. Custom hypothesis testing (simple) of within&#x02010;participant contrasts was performed for comparison of BH<sub>4</sub> versus placebo, in which treatment order was entered as a between&#x02010;participant factor to investigate whether the order in which BH<sub>4</sub> and placebo were received influenced the outcome. In post hoc tests, the effect of individual treatments was determined using paired Student <italic>t</italic> tests with Bonferroni adjustment for 2 comparisons. In addition, in post hoc tests, the use of methotrexate (MTX) was entered as a between&#x02010;participant factor to establish whether dyhydrofolate reductase inhibitor use influenced the BH<sub>4</sub> response. For the skewed variables (CRP and ESR), log&#x02010;transformed values were used for the analyses. Differences between the RA and control groups were determined using the unpaired Student <italic>t</italic> test. A probability of &#x0003c;0.05 was considered significant. Data are given as mean&#x000b1;SD.</p><p>The authors had full access to the data and take full responsibility for its integrity. All authors have read and agreed to the manuscript as written.</p></sec></sec><sec id="jah31337-sec-0013"><title>Results</title><p>Thirty&#x02010;three patients with active RA (mean DAS28 4.21&#x000b1;1.06) were studied before and after oral BH<sub>4</sub> and placebo. The mean age of the participants was 57&#x000b1;12&#x000a0;years, and 27 were female. Overall, 18 and 15 participants concluded the acute and short&#x02010;term supplementation studies, respectively. There were no differences in age, BMI, DAS28, CRP, ESR, or blood pressure between groups; however, total cholesterol was slightly higher in the participants allocated to the short&#x02010;term treatment group (4.4&#x000b1;0.9 versus 5.4&#x000b1;1.1&#x000a0;mmol/L; <italic>P</italic>=0.01). Baseline characteristics are detailed by group in Table&#x000a0;<xref rid="jah31337-tbl-0001" ref-type="table-wrap">1</xref>.</p><table-wrap id="jah31337-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics and Demographics</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Acute</th><th align="left" valign="top" rowspan="1" colspan="1">Short Term</th><th align="left" valign="top" rowspan="1" colspan="1">Controls</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value<xref ref-type="fn" rid="jah31337-note-0003">a</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sex, female/male, n/n</td><td align="left" rowspan="1" colspan="1">14/4</td><td align="left" rowspan="1" colspan="1">13/2</td><td align="left" rowspan="1" colspan="1">26/7</td><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">55&#x000b1;13</td><td align="left" rowspan="1" colspan="1">59&#x000b1;11</td><td align="left" rowspan="1" colspan="1">56&#x000b1;11</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">RA years</td><td align="left" rowspan="1" colspan="1">12&#x000b1;10</td><td align="left" rowspan="1" colspan="1">14&#x000b1;9</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg</td><td align="left" rowspan="1" colspan="1">71.4&#x000b1;14.3</td><td align="left" rowspan="1" colspan="1">70.9&#x000b1;10.1</td><td align="left" rowspan="1" colspan="1">71.8&#x000b1;16.2</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">BH<sub>4</sub> dose, mg/kg</td><td align="left" rowspan="1" colspan="1">5.8&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">5.8&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">25.8&#x000b1;4.5</td><td align="left" rowspan="1" colspan="1">26.7&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">26.2&#x000b1;5.2</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic BP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">126&#x000b1;17</td><td align="left" rowspan="1" colspan="1">125&#x000b1;13</td><td align="left" rowspan="1" colspan="1">121&#x000b1;9</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic BP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">73&#x000b1;9</td><td align="left" rowspan="1" colspan="1">77&#x000b1;9</td><td align="left" rowspan="1" colspan="1">77&#x000b1;7</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">MAP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">92&#x000b1;12</td><td align="left" rowspan="1" colspan="1">94&#x000b1;11</td><td align="left" rowspan="1" colspan="1">91&#x000b1;7</td><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate, bpm</td><td align="left" rowspan="1" colspan="1">74&#x000b1;12</td><td align="left" rowspan="1" colspan="1">68&#x000b1;12</td><td align="left" rowspan="1" colspan="1">66&#x000b1;9<xref ref-type="fn" rid="jah31337-note-0004">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">aPWV, m/s</td><td align="left" rowspan="1" colspan="1">7.87&#x000b1;2.24</td><td align="left" rowspan="1" colspan="1">7.79&#x000b1;1.15</td><td align="left" rowspan="1" colspan="1">6.8&#x000b1;1.03<xref ref-type="fn" rid="jah31337-note-0004">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Augmentation index, %</td><td align="left" rowspan="1" colspan="1">26&#x000b1;12</td><td align="left" rowspan="1" colspan="1">31&#x000b1;12</td><td align="left" rowspan="1" colspan="1">23&#x000b1;12</td><td align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Brachial diameter, mm</td><td align="left" rowspan="1" colspan="1">3.98&#x000b1;0.72</td><td align="left" rowspan="1" colspan="1">3.91&#x000b1;0.51</td><td align="left" rowspan="1" colspan="1">3.62&#x000b1;0.61<xref ref-type="fn" rid="jah31337-note-0004">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">FMD, %</td><td align="left" rowspan="1" colspan="1">3.17&#x000b1;2.68</td><td align="left" rowspan="1" colspan="1">3.67&#x000b1;1.92</td><td align="left" rowspan="1" colspan="1">6.16&#x000b1;3.63<xref ref-type="fn" rid="jah31337-note-0004">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">GTN, %</td><td align="left" rowspan="1" colspan="1">9.39&#x000b1;4.38</td><td align="left" rowspan="1" colspan="1">7.64&#x000b1;3..04</td><td align="left" rowspan="1" colspan="1">9.42&#x000b1;5.41</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">DAS28</td><td align="left" rowspan="1" colspan="1">4.34&#x000b1;0.92</td><td align="left" rowspan="1" colspan="1">4.05&#x000b1;1.22</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP, mg/L</td><td align="left" rowspan="1" colspan="1">6.50&#x000b1;5.90</td><td align="left" rowspan="1" colspan="1">4.80&#x000b1;4.07</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">ESR, mm/h</td><td align="left" rowspan="1" colspan="1">25&#x000b1;25</td><td align="left" rowspan="1" colspan="1">16&#x000b1;14</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">TC, mmol/L</td><td align="left" rowspan="1" colspan="1">4.4&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">5.4&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">5.2&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin, n</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti&#x02013;TNF&#x02010;&#x003b1;, n</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Methotrexate, n</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Other DMARDs, n</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">NSAIDs, n</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Prednisolone, n (mg/day)</td><td align="left" rowspan="1" colspan="1">7 (4.7&#x000b1;1.5)</td><td align="left" rowspan="1" colspan="1">2 (7.50&#x000b1;3.5)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.1 (0.1)</td></tr></tbody></table><table-wrap-foot><fn id="jah31337-note-0002"><p>Values represent mean&#x000b1;SD. Significance was determined using an unpaired Student <italic>t</italic> test. BMI indicates body mass index; BP, blood pressure; bpm, beats per minute; CRP, C&#x02010;reactive protein; DAS28, disease activity score; DMARDs, disease&#x02010;modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; NSAIDs, nonsteroidal anti&#x02010;inflammatory drugs; TC, total cholesterol; TNF&#x02010;&#x003b1;, tumor necrosis factor &#x003b1;.</p></fn><fn id="jah31337-note-0003"><label>a</label><p>
<italic>P</italic> value for the comparison between acute and short&#x02010;term study participants.</p></fn><fn id="jah31337-note-0004"><label>b</label><p>
<italic>P</italic>&#x0003c;0.05 between RA patients and control participants.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><sec id="jah31337-sec-0014"><title>Acute BH<sub>4</sub> Supplementation</title><p>The effect of BH<sub>4</sub> supplementation on hemodynamics and vascular function are detailed in Table&#x000a0;<xref rid="jah31337-tbl-0002" ref-type="table-wrap">2</xref>. Following a single dose of BH<sub>4</sub>, there was a significant increase in the FMD response, whereas placebo had no effect (+3.57&#x000b1;4.14% versus +1.01&#x000b1;3.12%, between treatments; <italic>P</italic>=0.03) (Figure&#x000a0;<xref rid="jah31337-fig-0002" ref-type="fig">2</xref>A). The order in which the treatments were given did not affect the outcome (<italic>P</italic>=0.8). Baseline diameter of brachial artery or response to sublingual glyceryl trinitrate did not change following the treatment. There were no significant differences between the changes in blood pressure, heart rate, AIx, brachial pulse wave velocity, or aPWV (Figure&#x000a0;<xref rid="jah31337-fig-0002" ref-type="fig">2</xref>B) following BH<sub>4</sub> or placebo.</p><table-wrap id="jah31337-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Change in Disease Activity, Inflammation, and Hemodynamic Parameters Following BH<sub>4</sub>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Acute</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Short Term</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">BH<sub>4</sub>
</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo</th><th align="left" valign="top" rowspan="1" colspan="1">ANOVA <italic>P</italic> Value</th><th align="left" valign="top" rowspan="1" colspan="1">BH<sub>4</sub>
</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo</th><th align="left" valign="top" rowspan="1" colspan="1">ANOVA <italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DAS28</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.02&#x000b1;0.46</td><td align="left" rowspan="1" colspan="1">&#x02212;0.09&#x000b1;.43</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP, mg/L</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02212;0.79&#x000b1;2.6</td><td align="left" rowspan="1" colspan="1">&#x02212;0.93&#x000b1;3.17</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">ESR, mm/h</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0&#x000b1;7</td><td align="left" rowspan="1" colspan="1">1&#x000b1;5</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">&#x02212;2&#x000b1;13</td><td align="left" rowspan="1" colspan="1">&#x02212;6&#x000b1;10</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">&#x02212;4&#x000b1;11</td><td align="left" rowspan="1" colspan="1">&#x02212;4&#x000b1;8</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">&#x02212;3&#x000b1;7</td><td align="left" rowspan="1" colspan="1">&#x02212;2&#x000b1;6</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">0&#x000b1;5</td><td align="left" rowspan="1" colspan="1">&#x02212;1&#x000b1;7</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">MAP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">&#x02212;3&#x000b1;9</td><td align="left" rowspan="1" colspan="1">&#x02212;5&#x000b1;8</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">&#x02212;2&#x000b1;7</td><td align="left" rowspan="1" colspan="1">&#x02212;3&#x000b1;7</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">HR, bpm</td><td align="left" rowspan="1" colspan="1">&#x02212;6&#x000b1;7</td><td align="left" rowspan="1" colspan="1">&#x02212;6&#x000b1;7</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">0&#x000b1;8</td><td align="left" rowspan="1" colspan="1">0&#x000b1;7</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">AIx, %</td><td align="left" rowspan="1" colspan="1">&#x02212;1&#x000b1;7</td><td align="left" rowspan="1" colspan="1">0&#x000b1;6</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">&#x02212;2&#x000b1;7</td><td align="left" rowspan="1" colspan="1">&#x02212;1&#x000b1;5</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">bPWV, m/s</td><td align="left" rowspan="1" colspan="1">&#x02212;0.14&#x000b1;0.74</td><td align="left" rowspan="1" colspan="1">0.09&#x000b1;0.77</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">0.07&#x000b1;1.14</td><td align="left" rowspan="1" colspan="1">&#x02212;0.25&#x000b1;0.52</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">aPWV, m/s</td><td align="left" rowspan="1" colspan="1">&#x02212;0.13&#x000b1;0.58</td><td align="left" rowspan="1" colspan="1">&#x02212;0.22&#x000b1;0.43</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">&#x02212;0.22&#x000b1;1.33</td><td align="left" rowspan="1" colspan="1">&#x02212;0.25&#x000b1;0.51</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Adjusted aPWV, m/s</td><td align="left" rowspan="1" colspan="1">0.15&#x000b1;0.82</td><td align="left" rowspan="1" colspan="1">0.31&#x000b1;0.80</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">&#x02212;0.22&#x000b1;1.27</td><td align="left" rowspan="1" colspan="1">0.28&#x000b1;0.72</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Brachial diameter, mm</td><td align="left" rowspan="1" colspan="1">0.14&#x000b1;0.37</td><td align="left" rowspan="1" colspan="1">&#x02212;0.02&#x000b1;0.40</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">&#x02212;0.17&#x000b1;0.40</td><td align="left" rowspan="1" colspan="1">0.04&#x000b1;0.39</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">FMD, %</td><td align="left" rowspan="1" colspan="1">3.57&#x000b1;4.14<xref ref-type="fn" rid="jah31337-note-0006">a</xref>
</td><td align="left" rowspan="1" colspan="1">1.01&#x000b1;3.12</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">3.69&#x000b1;4.90<xref ref-type="fn" rid="jah31337-note-0007">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.19&#x000b1;2.51</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">GTN, %</td><td align="left" rowspan="1" colspan="1">&#x02212;2.8&#x000b1;5.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1.8&#x000b1;2.7</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">0.36&#x000b1;2.02</td><td align="left" rowspan="1" colspan="1">1.33&#x000b1;2.07</td><td align="left" rowspan="1" colspan="1">0.3</td></tr></tbody></table><table-wrap-foot><fn id="jah31337-note-0005"><p>Values represent mean change&#x000b1;SD. Significance was determined using 2&#x02010;way repeated&#x02010;measures ANOVA. The effect of individual treatments was determined in post hoc tests with Bonferroni correction for 2 comparisons when overall significance in ANOVA was <italic>P</italic>&#x0003c;0.05. Results of these comparisons are indicated by asterisks. aPWV indicates aortic pulse wave velocity; bpm, beats per minute; bPWV, brachial pulse wave velocity; CRP, C&#x02010;reactive protein; DAS28, disease activity score; DBP, diastolic blood pressure; ESR, erythrocyte sedimentation rate; FMD, flow&#x02010;mediated dilatation; GTN, glyceryl trinitrate; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure.</p></fn><fn id="jah31337-note-0006"><label>a</label><p>
<italic>P</italic>=0.015.</p></fn><fn id="jah31337-note-0007"><label>b</label><p>
<italic>P</italic>=0.002.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah31337-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The effect of BH<sub>4</sub> 400&#x000a0;mg. Data represent means and <styled-content style="fixed-case">SEM</styled-content>. Significance was determined using 2&#x02010;way repeated&#x02010;measures <styled-content style="fixed-case">ANOVA</styled-content> and Bonferroni&#x02010;corrected post hoc tests. Red represents <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub>; blue represents placebo. A, Endothelial function was measured before and 3&#x000a0;hours after <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> and placebo in random order. <styled-content style="fixed-case">ANOVA</styled-content>:<italic> P</italic>=0.03 between groups; post hoc <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub>: <italic>P</italic>=0.015; placebo: <italic>P</italic>=0.5. B, Aortic stiffness was measured before and 3&#x000a0;hours after <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> and placebo in random order. <styled-content style="fixed-case">ANOVA</styled-content> between groups: <italic>P</italic>=0.6; post hoc <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub>: <italic>P</italic>=0.5; placebo: <italic>P</italic>=0.6. C, Endothelial function was measured before and 7&#x000a0;days after <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> and placebo in random order. <styled-content style="fixed-case">ANOVA</styled-content> between groups: <italic>P</italic>=0.02; post hoc <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub>: <italic>P</italic>=0.002; placebo: <italic>P</italic>=0.4. D, Aortic stiffness was measured before and 7&#x000a0;days after <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub> and placebo in random order. <styled-content style="fixed-case">ANOVA</styled-content> between groups: <italic>P</italic>=0.9; post hoc <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub>: <italic>P</italic>=0.5; placebo: <italic>P</italic>=0.5. aPWV indicates aortic pulse wave velocity; <styled-content style="fixed-case">BH</styled-content>
<sub>4</sub>, tetrahydrobiopterin; FMD, flow&#x02010;mediated dilatation.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-5-e002762-g002"/></fig></sec><sec id="jah31337-sec-0015"><title>Short&#x02010;Term BH<sub>4</sub> Supplementation</title><p>The 1&#x02010;week treatment with BH<sub>4</sub> led to a significant increase in FMD compared with placebo (+3.69&#x000b1;4.90% versus +0.19&#x000b1;2.51%, between treatments; <italic>P</italic>=0.02) (Figure&#x000a0;<xref rid="jah31337-fig-0002" ref-type="fig">2</xref>C). The order in which the treatments were given did not affect the outcome (<italic>P</italic>=0.7). Again, there was no change in blood pressure or aPWV (Figure&#x000a0;<xref rid="jah31337-fig-0002" ref-type="fig">2</xref>D).</p><p>Seventeen of the 33 RA patients were receiving MTX, a dyhydrofolate reductase inhibitor, at the time of the study. Post hoc testing demonstrated that MTX had no impact on the effect of BH<sub>4</sub> on endothelial function (<italic>P</italic>=0.34) for the drug&#x000d7;visit&#x000d7;MTX interaction. If anything, there was a nonsignificant trend demonstrating that those on MTX had greater improvement of FMD following BH<sub>4</sub> in comparison to those not on MTX (+4.6&#x000b1;5.0% versus +2.49&#x000b1;3.40%; <italic>P</italic>=0.18,). This was despite no difference in baseline FMD (<italic>P</italic>=0.9) or brachial artery diameter (<italic>P</italic>=0.98).</p></sec><sec id="jah31337-sec-0016"><title>The Effect of BH<sub>4</sub> on Inflammatory Markers and Disease Activity</title><p>Following short&#x02010;term supplementation with BH<sub>4</sub> and placebo, there were no changes in CRP (&#x02212;0.79&#x000b1;2.6&#x000a0;versus &#x02212;0.93&#x000b1;3.17&#x000a0;mg/L; <italic>P</italic>=0.9), ESR (0&#x000b1;7&#x000a0;versus 1&#x000b1;5&#x000a0;mm/h; <italic>P</italic>=0.6), or DAS28 (0.02&#x000b1;0.46 versus &#x02212;0.09&#x000b1;0.43; <italic>P</italic>=0.4) (Table&#x000a0;<xref rid="jah31337-tbl-0002" ref-type="table-wrap">2</xref>.</p><p>There was no correlation between the change in FMD and change in aPWV following BH<sub>4</sub> (<italic>R</italic>=0.27; <italic>P</italic>=0.20); however, the change in FMD after BH<sub>4</sub> correlated negatively with age (<italic>R</italic>=&#x02212;0.44; <italic>P</italic>=0.01). Baseline aPWV was significantly (<italic>P</italic>&#x0003c;0.05) correlated with mean arterial pressure (<italic>R</italic>=0.52), age (<italic>R</italic>=0.52), CRP (<italic>R</italic>=0.39), and ESR (<italic>R</italic>=0.66).</p></sec><sec id="jah31337-sec-0017"><title>Baseline Comparison With Healthy Controls</title><p>The mean age of the healthy control group was 56&#x000b1;11&#x000a0;years. At baseline, RA patients had reduced endothelial function in comparison to control participants (FMD 3.39&#x000b1;2.36% versus 6.16&#x000b1;3.63%; <italic>P</italic>=0.001). After treatment with BH<sub>4</sub>, the FMD response was no longer different between RA patients and controls (6.82&#x000b1;4.83% versus 6.16&#x000b1;3.63%; <italic>P</italic>=0.5). Baseline aPWV was higher in the RA group compared with controls (7.83&#x000b1;1.80&#x000a0;versus 6.8&#x000b1;1.03&#x000a0;m/s; <italic>P</italic>=0.006), whereas blood pressure did not differ between the groups (Table&#x000a0;<xref rid="jah31337-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec></sec><sec id="jah31337-sec-0018"><title>Discussion</title><p>The main findings of the present study are that both acute and short&#x02010;term therapy with BH<sub>4</sub> significantly improves endothelial function, as assessed by vasodilatory response to reactive hyperemia in patients with active RA, but does not affect blood pressure, AIx, aPWV, or brachial pulse wave velocity. These findings suggest that modulation of endothelial function does not ameliorate arterial stiffness in RA.</p><p>The current study demonstrates, for the first time, that oral BH<sub>4</sub> supplementation improves endothelial function in patients with RA by &#x02248;3.5%, restoring it to levels comparable to those of healthy controls. The improvement of FMD was inversely associated with age, suggesting that endothelial dysfunction in younger RA patients may be more reversible than in older patients. FMD has been validated recently as a surrogate marker of future cardiovascular risk. Yeboah et&#x000a0;al demonstrated that FMD is a predictor of incident cardiovascular events and that it improves the classification of participants as low, intermediate, and high CVD risk compared with the Framingham risk score in a large population&#x02010;based cohort.<xref rid="jah31337-bib-0004" ref-type="ref">4</xref> The mean FMD in their whole cohort was 4.4&#x000b1;2.8% versus 3.4&#x000b1;2.5% in incident cases, suggesting that the improvement seen in our study is likely to have a clinical impact on cardiovascular risk reduction in patients with RA.</p><p>Previous studies have demonstrated that intra&#x02010;arterial administration of BH<sub>4</sub> improves endothelium&#x02010;dependent dilatation in patients with hypercholesterolemia,<xref rid="jah31337-bib-0027" ref-type="ref">27</xref> coronary artery disease,<xref rid="jah31337-bib-0028" ref-type="ref">28</xref> and type II diabetes.<xref rid="jah31337-bib-0029" ref-type="ref">29</xref> Oral BH<sub>4</sub> supplementation also improves endothelial function in elderly patients,<xref rid="jah31337-bib-0030" ref-type="ref">30</xref> in long&#x02010;term smokers,<xref rid="jah31337-bib-0031" ref-type="ref">31</xref> and in patients with hypercholesterolemia<xref rid="jah31337-bib-0032" ref-type="ref">32</xref> and hypertension.<xref rid="jah31337-bib-0033" ref-type="ref">33</xref> Conversely, Cunnington et&#x000a0;al showed that although oral BH<sub>4</sub> led to an &#x02248;2.5&#x02010;fold increase of plasma BH<sub>4</sub> levels in patients with established coronary artery disease, it had no effect on vascular function or superoxide production because of systemic oxidation of BH<sub>4</sub> to BH<sub>2</sub>.<xref rid="jah31337-bib-0019" ref-type="ref">19</xref> The impact of BH<sub>4</sub> on endothelial function has not been assessed previously in RA; however, other interventions (eg, individually designed exercise program) have been shown to improve endothelial function in RA patients.<xref rid="jah31337-bib-0039" ref-type="ref">39</xref> Because intracellular BH<sub>4</sub> levels are regulated by de novo synthesis of BH<sub>4</sub> from guanosine triphosphate and through recycling of BH<sub>2</sub> to BH<sub>4</sub> via dyhydrofolate reductase,<xref rid="jah31337-bib-0040" ref-type="ref">40</xref> use of dyhydrofolate reductase inhibitors (eg, disease&#x02010;modifying antirheumatic drugs, MTX) may inhibit the bioavailability of BH<sub>4</sub> in the endothelium. Nevertheless, we found no difference in the effect of BH<sub>4</sub> supplementation on endothelial function between those RA patients on MTX and those not receiving MTX. A trend suggested that those patients on MTX had a greater increase in FMD following BH<sub>4</sub> supplementation, perhaps because of reduced levels of inflammation. Notably, our study was not powered to look at this difference.</p><p>We and others have demonstrated that patients with RA have increased aortic stiffening in comparison to healthy participants,<xref rid="jah31337-bib-0010" ref-type="ref">10</xref>, <xref rid="jah31337-bib-0014" ref-type="ref">14</xref>, <xref rid="jah31337-bib-0015" ref-type="ref">15</xref>, <xref rid="jah31337-bib-0016" ref-type="ref">16</xref> and that can be reversed with immunomodulatory therapy.<xref rid="jah31337-bib-0010" ref-type="ref">10</xref>, <xref rid="jah31337-bib-0012" ref-type="ref">12</xref>, <xref rid="jah31337-bib-0041" ref-type="ref">41</xref> Our previous studies suggested a link between arterial stiffness and endothelial function,<xref rid="jah31337-bib-0017" ref-type="ref">17</xref>, <xref rid="jah31337-bib-0018" ref-type="ref">18</xref> but it is unclear if this relationship is causal or if they occur in parallel in response to common drivers such as increased inflammation. Interestingly, in the present study, neither a single dose nor short&#x02010;term supplementation with oral BH<sub>4</sub> led to a change in aPWV, brachial pulse wave velocity, AIx, or blood pressure in comparison to placebo. Park et&#x000a0;al recently demonstrated in patients with chronic kidney disease that 6R&#x02010;BH<sub>4</sub> significantly improved AIx<xref rid="jah31337-bib-0042" ref-type="ref">42</xref>; however, there was also a drop in blood pressure, and it appears that the change in AIx was not corrected for change in mean arterial pressure, only for heart rate. Similarly, Porkert et&#x000a0;al showed a 15&#x02010;mm Hg reduction in systolic blood pressure following 8&#x02010;week treatment with BH<sub>4</sub> 400&#x000a0;mg in hypertensive patients, but this study was not placebo controlled.<xref rid="jah31337-bib-0033" ref-type="ref">33</xref> In healthy older men, BH<sub>4</sub> was shown to reduce carotid artery compliance, but there was a confounding fall in systolic blood pressure.<xref rid="jah31337-bib-0043" ref-type="ref">43</xref> In postmenopausal women, however, Moreau et&#x000a0;al showed an improvement in carotid artery compliance and FMD response following a single dose of oral BH<sub>4</sub> without change in mean arterial pressure.<xref rid="jah31337-bib-0044" ref-type="ref">44</xref>
</p><p>Our study also provided evidence about causality for endothelial function and aortic stiffness. We demonstrated previously that under resting conditions, local NO production modulates distensibility of muscular iliac artery in humans and that exogenous NO increases arterial distensibility<xref rid="jah31337-bib-0018" ref-type="ref">18</xref>; however, data relating to elastic aorta are more controversial. A recent study by Butlin et&#x000a0;al showed that exogenous NO donor sodium nitroprusside does not alter aortic stiffness in&#x000a0;vivo in rats.<xref rid="jah31337-bib-0045" ref-type="ref">45</xref> Nevertheless, numerous studies,<xref rid="jah31337-bib-0010" ref-type="ref">10</xref>, <xref rid="jah31337-bib-0011" ref-type="ref">11</xref>, <xref rid="jah31337-bib-0046" ref-type="ref">46</xref> including ours, have demonstrated a reduction in aortic stiffness, which mirrors the changes in endothelial function, following anti&#x02010;inflammatory or cholesterol&#x02010;lowering therapies. The current study clearly demonstrated that improvement of endothelial function, without change in inflammation or lipids, does not lead to reduction of aortic stiffness, strongly suggesting that there is no direct causal link between aortic stiffness and endothelial function. We cannot exclude the possibility that this finding is specific to RA because previous studies have demonstrated changes in aPWV in healthy participants in acute models of induced inflammation.<xref rid="jah31337-bib-0047" ref-type="ref">47</xref>, <xref rid="jah31337-bib-0048" ref-type="ref">48</xref>
</p><sec id="jah31337-sec-0019"><title>Limitations</title><p>We did not assess serum BH<sub>4</sub> and BH<sub>2</sub> levels in our study; however, numerous studies have demonstrated that supplementation with 6R&#x02010;BH<sub>4</sub> leads to increase in serum BH<sub>4</sub> levels.<xref rid="jah31337-bib-0019" ref-type="ref">19</xref>, <xref rid="jah31337-bib-0032" ref-type="ref">32</xref> Moreover, we chose the time points based on published findings. Fiege et&#x000a0;al demonstrated that the maximal plasma biopterin levels peaked between 1 and 4&#x000a0;hours, with median peak of 3&#x000a0;hours and maximum concentration of 258.7 to 295.0&#x000a0;nmol/L for 10&#x000a0;mg/kg; even 24&#x000a0;hours after administration, 6R&#x02010;BH<sub>4</sub> levels were still 4&#x02013;5 times the basal values.<xref rid="jah31337-bib-0035" ref-type="ref">35</xref> Moreover, our treatment period of 1&#x02010;week was very short, and we can neither extrapolate these results to what may be the chronic effects of BH<sub>4</sub> supplementation in patients with RA nor predict whether it may have beneficial effects on future cardiovascular events.</p></sec></sec><sec id="jah31337-sec-0020"><title>Conclusion</title><p>This study shows for the first time in patients with RA that oral BH<sub>4</sub> improves endothelial function as measured by a response to reactive hyperemia. These findings suggest that recoupling of eNOS using cofactor BH<sub>4</sub> may provide a rational therapeutic approach to prevent CVD in patients with chronic inflammatory diseases. BH<sub>4</sub> supplementation did not appear to reduce aortic stiffness, suggesting that endothelial dysfunction is not a pathophysiology behind aortic stiffening in RA and that these conditions may just exist in parallel, both influenced by common risk factors such as inflammation and increased reactive oxygen species production.</p></sec><sec id="jah31337-sec-0021"><title>Sources of Funding</title><p>M&#x000e4;ki&#x02010;Pet&#x000e4;j&#x000e4; and Wilkinson were funded by British Heart Foundation. Wilkinson, Cheriyan and Shenker received funding from the Comprehensive Local Research Network and Wilkinson and Cheriyan from the National Institute for Health Research: Cambridge Biomedical Research Centre.</p></sec><sec id="jah31337-sec-0022"><title>Disclosures</title><p>None.</p></sec></body><back><ref-list content-type="cited-references" id="jah31337-bibl-0001"><title>References</title><ref id="jah31337-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah31337-cit-0001">
<string-name>
<surname>Wolfe</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Sibley</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Fries</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Bloch</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Spitz</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Haga</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kleinheksel</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Cathey</surname>
<given-names>MA</given-names>
</string-name>. <article-title>The mortality of rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source>. <year>1994</year>;<volume>37</volume>:<fpage>481</fpage>&#x02013;<lpage>494</lpage>.<pub-id pub-id-type="pmid">8147925</pub-id></mixed-citation></ref><ref id="jah31337-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah31337-cit-0002">
<string-name>
<surname>Symmons</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Prior</surname>
<given-names>P</given-names>
</string-name>. <article-title>Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well</article-title>. <source>J Rheumatol</source>. <year>1998</year>;<volume>25</volume>:<fpage>1072</fpage>&#x02013;<lpage>1077</lpage>.<pub-id pub-id-type="pmid">9632066</pub-id></mixed-citation></ref><ref id="jah31337-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah31337-cit-0003">
<string-name>
<surname>Lind</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Berglund</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Larsson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sundstrom</surname>
<given-names>J</given-names>
</string-name>. <article-title>Endothelial function in resistance and conduit arteries and 5&#x02010;year risk of cardiovascular disease</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>1545</fpage>&#x02013;<lpage>1551</lpage>.<pub-id pub-id-type="pmid">21444885</pub-id></mixed-citation></ref><ref id="jah31337-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah31337-cit-0004">
<string-name>
<surname>Yeboah</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Folsom</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Polak</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Post</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lima</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Crouse</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Herrington</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Predictive value of brachial flow&#x02010;mediated dilation for incident cardiovascular events in a population&#x02010;based study: the Multi&#x02010;Ethnic Study of Atherosclerosis</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>:<fpage>502</fpage>&#x02013;<lpage>509</lpage>.<pub-id pub-id-type="pmid">19635967</pub-id></mixed-citation></ref><ref id="jah31337-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah31337-cit-0005">
<string-name>
<surname>Hansel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lassig</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pistrosch</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Passauer</surname>
<given-names>J</given-names>
</string-name>. <article-title>Endothelial dysfunction in young patients with long&#x02010;term rheumatoid arthritis and low disease activity</article-title>. <source>Atherosclerosis</source>. <year>2003</year>;<volume>170</volume>:<fpage>177</fpage>&#x02013;<lpage>180</lpage>.<pub-id pub-id-type="pmid">12957697</pub-id></mixed-citation></ref><ref id="jah31337-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah31337-cit-0006">
<string-name>
<surname>Vaudo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Marchesi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gerli</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Allegrucci</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Giordano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Siepi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Pirro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shoenfeld</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Schillaci</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mannarino</surname>
<given-names>E</given-names>
</string-name>. <article-title>Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity</article-title>. <source>Ann Rheum Dis</source>. <year>2004</year>;<volume>63</volume>:<fpage>31</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">14672888</pub-id></mixed-citation></ref><ref id="jah31337-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah31337-cit-0007">
<string-name>
<surname>Bergholm</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Leirisalo&#x02010;Repo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vehkavaara</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Makimattila</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Taskinen</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Yki&#x02010;Jarvinen</surname>
<given-names>H</given-names>
</string-name>. <article-title>Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2002</year>;<volume>22</volume>:<fpage>1637</fpage>&#x02013;<lpage>1641</lpage>.<pub-id pub-id-type="pmid">12377742</pub-id></mixed-citation></ref><ref id="jah31337-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah31337-cit-0008">
<string-name>
<surname>Herbrig</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Haensel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oelschlaegel</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Pistrosch</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Foerster</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Passauer</surname>
<given-names>J</given-names>
</string-name>. <article-title>Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells</article-title>. <source>Ann Rheum Dis</source>. <year>2006</year>;<volume>65</volume>:<fpage>157</fpage>&#x02013;<lpage>163</lpage>.<pub-id pub-id-type="pmid">15975971</pub-id></mixed-citation></ref><ref id="jah31337-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah31337-cit-0009">
<string-name>
<surname>Maki&#x02010;Petaja</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Cheriyan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Booth</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wallace</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Ashby</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>McEniery</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>IB</given-names>
</string-name>. <article-title>Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction</article-title>. <source>Int J Cardiol</source>. <year>2008</year>;<volume>129</volume>:<fpage>399</fpage>&#x02013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">18571252</pub-id></mixed-citation></ref><ref id="jah31337-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah31337-cit-0010">
<string-name>
<surname>Maki&#x02010;Petaja</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Booth</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Wallace</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Yasmin</surname>
</string-name>, <string-name>
<surname>Bearcroft</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Harish</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Furlong</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McEniery</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>IB</given-names>
</string-name>. <article-title>Rheumatoid arthritis is associated with increased aortic pulse&#x02010;wave velocity, which is reduced by anti&#x02010;tumor necrosis factor&#x02010;alpha therapy</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>114</volume>:<fpage>1185</fpage>&#x02013;<lpage>1192</lpage>.<pub-id pub-id-type="pmid">16952987</pub-id></mixed-citation></ref><ref id="jah31337-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah31337-cit-0011">
<string-name>
<surname>Maki&#x02010;Petaja</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Elkhawad</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cheriyan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Joshi</surname>
<given-names>FR</given-names>
</string-name>, <string-name>
<surname>Ostor</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Rudd</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>IB</given-names>
</string-name>. <article-title>Anti&#x02010;tumor necrosis factor&#x02010;alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>126</volume>:<fpage>2473</fpage>&#x02013;<lpage>2480</lpage>.<pub-id pub-id-type="pmid">23095282</pub-id></mixed-citation></ref><ref id="jah31337-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah31337-cit-0012">
<string-name>
<surname>Hurlimann</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Forster</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Noll</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Enseleit</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Chenevard</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Distler</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Bechir</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Spieker</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Neidhart</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Michel</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Gay</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Luscher</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Gay</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ruschitzka</surname>
<given-names>F</given-names>
</string-name>. <article-title>Anti&#x02010;tumor necrosis factor&#x02010;alpha treatment improves endothelial function in patients with rheumatoid arthritis</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>:<fpage>2184</fpage>&#x02013;<lpage>2187</lpage>.<pub-id pub-id-type="pmid">12390945</pub-id></mixed-citation></ref><ref id="jah31337-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah31337-cit-0013">
<string-name>
<surname>Vlachopoulos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Aznaouridis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Stefanadis</surname>
<given-names>C</given-names>
</string-name>. <article-title>Prediction of cardiovascular events and all&#x02010;cause mortality with arterial stiffness: a systematic review and meta&#x02010;analysis</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>1318</fpage>&#x02013;<lpage>1327</lpage>.<pub-id pub-id-type="pmid">20338492</pub-id></mixed-citation></ref><ref id="jah31337-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah31337-cit-0014">
<string-name>
<surname>Turesson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jacobsson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ryden Ahlgren</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sturfelt</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wollmer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lanne</surname>
<given-names>T</given-names>
</string-name>. <article-title>Increased stiffness of the abdominal aorta in women with rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source>. <year>2005</year>;<volume>44</volume>:<fpage>896</fpage>&#x02013;<lpage>901</lpage>.<pub-id pub-id-type="pmid">15784628</pub-id></mixed-citation></ref><ref id="jah31337-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah31337-cit-0015">
<string-name>
<surname>Van Doornum</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>McColl</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Jenkins</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Green</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Wicks</surname>
<given-names>IP</given-names>
</string-name>. <article-title>Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in&#x000a0;vivo tests of vascular function</article-title>. <source>Arthritis Rheum</source>. <year>2003</year>;<volume>48</volume>:<fpage>72</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">12528106</pub-id></mixed-citation></ref><ref id="jah31337-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah31337-cit-0016">
<string-name>
<surname>Roman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Devereux</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Lockshin</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Paget</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Crow</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Sammaritano</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Levine</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Shankar</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Moeller</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Salmon</surname>
<given-names>JE</given-names>
</string-name>. <article-title>Arterial stiffness in chronic inflammatory diseases</article-title>. <source>Hypertension</source>. <year>2005</year>;<volume>46</volume>:<fpage>1</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15911739</pub-id></mixed-citation></ref><ref id="jah31337-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah31337-cit-0017">
<string-name>
<surname>Wilkinson</surname>
<given-names>IB</given-names>
</string-name>, <string-name>
<surname>Qasem</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McEniery</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Avolio</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Cockcroft</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Nitric oxide regulates local arterial distensibility in&#x000a0;vivo</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>105</volume>:<fpage>213</fpage>&#x02013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">11790703</pub-id></mixed-citation></ref><ref id="jah31337-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah31337-cit-0018">
<string-name>
<surname>Schmitt</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Avolio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Qasem</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McEniery</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Butlin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>IB</given-names>
</string-name>, <string-name>
<surname>Cockcroft</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Basal NO locally modulates human iliac artery function in&#x000a0;vivo</article-title>. <source>Hypertension</source>. <year>2005</year>;<volume>46</volume>:<fpage>227</fpage>&#x02013;<lpage>231</lpage>.<pub-id pub-id-type="pmid">15867142</pub-id></mixed-citation></ref><ref id="jah31337-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah31337-cit-0019">
<string-name>
<surname>Cunnington</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Van</surname>
<given-names>Assche T</given-names>
</string-name>, <string-name>
<surname>Shirodaria</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kylintireas</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Lindsay</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Antoniades</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Margaritis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cerrato</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Crabtree</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Francis</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Sayeed</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ratnatunga</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pillai</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Choudhury</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Neubauer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Channon</surname>
<given-names>KM</given-names>
</string-name>. <article-title>Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>125</volume>:<fpage>1356</fpage>&#x02013;<lpage>1366</lpage>.<pub-id pub-id-type="pmid">22315282</pub-id></mixed-citation></ref><ref id="jah31337-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah31337-cit-0020">
<string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Reece</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pimental</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Zou</surname>
<given-names>MH</given-names>
</string-name>. <article-title>Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase&#x02010;derived superoxide and peroxynitrite</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2006</year>;<volume>26</volume>:<fpage>2688</fpage>&#x02013;<lpage>2695</lpage>.<pub-id pub-id-type="pmid">17023679</pub-id></mixed-citation></ref><ref id="jah31337-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah31337-cit-0021">
<string-name>
<surname>Gunnett</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Lund</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>McDowell</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Faraci</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Heistad</surname>
<given-names>DD</given-names>
</string-name>. <article-title>Mechanisms of inducible nitric oxide synthase&#x02010;mediated vascular dysfunction</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2005</year>;<volume>25</volume>:<fpage>1617</fpage>&#x02013;<lpage>1622</lpage>.<pub-id pub-id-type="pmid">15933248</pub-id></mixed-citation></ref><ref id="jah31337-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah31337-cit-0022">
<string-name>
<surname>Vasquez&#x02010;Vivar</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kalyanaraman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Martasek</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hogg</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Masters</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Karoui</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tordo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pritchard</surname>
<given-names>KA</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1998</year>;<volume>95</volume>:<fpage>9220</fpage>&#x02013;<lpage>9225</lpage>.<pub-id pub-id-type="pmid">9689061</pub-id></mixed-citation></ref><ref id="jah31337-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah31337-cit-0023">
<string-name>
<surname>Kuzkaya</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Weissmann</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Dikalov</surname>
<given-names>S</given-names>
</string-name>. <article-title>Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric&#x02010;oxide synthase</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>:<fpage>22546</fpage>&#x02013;<lpage>22554</lpage>.<pub-id pub-id-type="pmid">12692136</pub-id></mixed-citation></ref><ref id="jah31337-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah31337-cit-0024">
<string-name>
<surname>Laursen</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Somers</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kurz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>McCann</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Warnholtz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Tarpey</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fukai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>
<given-names>DG</given-names>
</string-name>. <article-title>Endothelial regulation of vasomotion in apoE&#x02010;deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>103</volume>:<fpage>1282</fpage>&#x02013;<lpage>1288</lpage>.<pub-id pub-id-type="pmid">11238274</pub-id></mixed-citation></ref><ref id="jah31337-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah31337-cit-0025">
<string-name>
<surname>Baskol</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Demir</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Baskol</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kilic</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ates</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Karakukcu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ustdal</surname>
<given-names>M</given-names>
</string-name>. <article-title>Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis</article-title>. <source>Cell Biochem Funct</source>. <year>2006</year>;<volume>24</volume>:<fpage>307</fpage>&#x02013;<lpage>311</lpage>.<pub-id pub-id-type="pmid">16142689</pub-id></mixed-citation></ref><ref id="jah31337-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah31337-cit-0026">
<string-name>
<surname>Vita</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Brennan</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Gokce</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Goormastic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shishehbor</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Penn</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Keaney</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Hazen</surname>
<given-names>SL</given-names>
</string-name>. <article-title>Serum myeloperoxidase levels independently predict endothelial dysfunction in humans</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>:<fpage>1134</fpage>&#x02013;<lpage>1139</lpage>.<pub-id pub-id-type="pmid">15326065</pub-id></mixed-citation></ref><ref id="jah31337-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah31337-cit-0027">
<string-name>
<surname>Stroes</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kastelein</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cosentino</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Erkelens</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wever</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Koomans</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Luscher</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rabelink</surname>
<given-names>T</given-names>
</string-name>. <article-title>Tetrahydrobiopterin restores endothelial function in hypercholesterolemia</article-title>. <source>J Clin Invest</source>. <year>1997</year>;<volume>99</volume>:<fpage>41</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">9011574</pub-id></mixed-citation></ref><ref id="jah31337-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah31337-cit-0028">
<string-name>
<surname>Setoguchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mohri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shimokawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takeshita</surname>
<given-names>A</given-names>
</string-name>. <article-title>Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2001</year>;<volume>38</volume>:<fpage>493</fpage>&#x02013;<lpage>498</lpage>.<pub-id pub-id-type="pmid">11499743</pub-id></mixed-citation></ref><ref id="jah31337-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah31337-cit-0029">
<string-name>
<surname>Settergren</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bohm</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Malmstrom</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Channon</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Pernow</surname>
<given-names>J</given-names>
</string-name>. <article-title>L&#x02010;arginine and tetrahydrobiopterin protects against ischemia/reperfusion&#x02010;induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease</article-title>. <source>Atherosclerosis</source>. <year>2009</year>;<volume>204</volume>:<fpage>73</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">18849028</pub-id></mixed-citation></ref><ref id="jah31337-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah31337-cit-0030">
<string-name>
<surname>Eskurza</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Myerburgh</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Kahn</surname>
<given-names>ZD</given-names>
</string-name>, <string-name>
<surname>Seals</surname>
<given-names>DR</given-names>
</string-name>. <article-title>Tetrahydrobiopterin augments endothelium&#x02010;dependent dilatation in sedentary but not in habitually exercising older adults</article-title>. <source>J Physiol</source>. <year>2005</year>;<volume>568</volume>:<fpage>1057</fpage>&#x02013;<lpage>1065</lpage>.<pub-id pub-id-type="pmid">16141271</pub-id></mixed-citation></ref><ref id="jah31337-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah31337-cit-0031">
<string-name>
<surname>Ueda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Matsuoka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Miyazaki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Usui</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Okuda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Imaizumi</surname>
<given-names>T</given-names>
</string-name>. <article-title>Tetrahydrobiopterin restores endothelial function in long&#x02010;term smokers</article-title>. <source>J Am Coll Cardiol</source>. <year>2000</year>;<volume>35</volume>:<fpage>71</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">10636262</pub-id></mixed-citation></ref><ref id="jah31337-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah31337-cit-0032">
<string-name>
<surname>Cosentino</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hurlimann</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Delli Gatti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chenevard</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Blau</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Alp</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Channon</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Eto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lerch</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Enseleit</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ruschitzka</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Volpe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Luscher</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Noll</surname>
<given-names>G</given-names>
</string-name>. <article-title>Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia</article-title>. <source>Heart</source>. <year>2008</year>;<volume>94</volume>:<fpage>487</fpage>&#x02013;<lpage>492</lpage>.<pub-id pub-id-type="pmid">17916662</pub-id></mixed-citation></ref><ref id="jah31337-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah31337-cit-0033">
<string-name>
<surname>Porkert</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sher</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Cheema</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Niessner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kolm</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Hooper</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Quyyumi</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Tetrahydrobiopterin: a novel antihypertensive therapy</article-title>. <source>J Hum Hypertens</source>. <year>2008</year>;<volume>22</volume>:<fpage>401</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">18322548</pub-id></mixed-citation></ref><ref id="jah31337-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah31337-cit-0034">
<string-name>
<surname>Cecelja</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chowienczyk</surname>
<given-names>P</given-names>
</string-name>. <article-title>Role of arterial stiffness in cardiovascular disease</article-title>. <source>JRSM Cardiovasc Dis</source>. <year>2012</year>;<volume>1</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="jah31337-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah31337-cit-0035">
<string-name>
<surname>Fiege</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ballhausen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kierat</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Leimbacher</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Goriounov</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schircks</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Thony</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Blau</surname>
<given-names>N</given-names>
</string-name>. <article-title>Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration</article-title>. <source>Mol Genet Metab</source>. <year>2004</year>;<volume>81</volume>:<fpage>45</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">14728990</pub-id></mixed-citation></ref><ref id="jah31337-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jah31337-cit-0036">
<string-name>
<surname>Wilkinson</surname>
<given-names>IB</given-names>
</string-name>, <string-name>
<surname>Fuchs</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Jansen</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Spratt</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Cockcroft</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis</article-title>. <source>J Hypertens</source>. <year>1998</year>;<volume>16</volume>:<fpage>2079</fpage>&#x02013;<lpage>2084</lpage>.<pub-id pub-id-type="pmid">9886900</pub-id></mixed-citation></ref><ref id="jah31337-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jah31337-cit-0037">
<string-name>
<surname>Mullen</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Thorne</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Deanfield</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>CJ</given-names>
</string-name>. <article-title>Non&#x02010;invasive assessment of endothelial function</article-title>. <source>Heart</source>. <year>1997</year>;<volume>77</volume>:<fpage>297</fpage>&#x02013;<lpage>298</lpage>.<pub-id pub-id-type="pmid">9155600</pub-id></mixed-citation></ref><ref id="jah31337-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jah31337-cit-0038">
<string-name>
<surname>Prevoo</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>van &#x02018;t Hof</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Kuper</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>van Leeuwen</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>van de Putte</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>van Riel</surname>
<given-names>PL</given-names>
</string-name>. <article-title>Modified disease activity scores that include twenty&#x02010;eight&#x02010;joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source>. <year>1995</year>;<volume>38</volume>:<fpage>44</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">7818570</pub-id></mixed-citation></ref><ref id="jah31337-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jah31337-cit-0039">
<string-name>
<surname>Metsios</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Stavropoulos&#x02010;Kalinoglou</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Veldhuijzen van Zanten</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Nightingale</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sandoo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dimitroulas</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kitas</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Koutedakis</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Individualised exercise improves endothelial function in patients with rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source>. <year>2014</year>;<volume>73</volume>:<fpage>748</fpage>&#x02013;<lpage>751</lpage>.<pub-id pub-id-type="pmid">23904472</pub-id></mixed-citation></ref><ref id="jah31337-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jah31337-cit-0040">
<string-name>
<surname>Channon</surname>
<given-names>KM</given-names>
</string-name>. <article-title>Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease</article-title>. <source>Trends Cardiovasc Med</source>. <year>2004</year>;<volume>14</volume>:<fpage>323</fpage>&#x02013;<lpage>327</lpage>.<pub-id pub-id-type="pmid">15596110</pub-id></mixed-citation></ref><ref id="jah31337-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jah31337-cit-0041">
<string-name>
<surname>Gonzalez&#x02010;Juanatey</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Testa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Castelo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Porrua</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Llorca</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gonzalez&#x02010;Gay</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long&#x02010;term treatment with anti&#x02010;tumor necrosis factor alpha antibody</article-title>. <source>Arthritis Rheum</source>. <year>2004</year>;<volume>51</volume>:<fpage>447</fpage>&#x02013;<lpage>450</lpage>.<pub-id pub-id-type="pmid">15188332</pub-id></mixed-citation></ref><ref id="jah31337-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jah31337-cit-0042">
<string-name>
<surname>Park</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sher</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lyles</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Deveaux</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Quyyumi</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Tetrahydrobiopterin lowers muscle sympathetic nerve activity and improves augmentation index in patients with chronic kidney disease</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2015</year>;<volume>308</volume>:<fpage>R208</fpage>&#x02013;<lpage>R218</lpage>.<pub-id pub-id-type="pmid">25477424</pub-id></mixed-citation></ref><ref id="jah31337-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jah31337-cit-0043">
<string-name>
<surname>Pierce</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Jablonski</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Seibert</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>DeVan</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Seals</surname>
<given-names>DR</given-names>
</string-name>. <article-title>Tetrahydrobiopterin supplementation enhances carotid artery compliance in healthy older men: a pilot study</article-title>. <source>Am J Hypertens</source>. <year>2012</year>;<volume>25</volume>:<fpage>1050</fpage>&#x02013;<lpage>1054</lpage>.<pub-id pub-id-type="pmid">22673017</pub-id></mixed-citation></ref><ref id="jah31337-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jah31337-cit-0044">
<string-name>
<surname>Moreau</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Meditz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Deane</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Kohrt</surname>
<given-names>WM</given-names>
</string-name>. <article-title>Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen&#x02010;deficient postmenopausal women</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2012</year>;<volume>302</volume>:<fpage>H1211</fpage>&#x02013;<lpage>H1218</lpage>.<pub-id pub-id-type="pmid">22245769</pub-id></mixed-citation></ref><ref id="jah31337-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jah31337-cit-0045">
<string-name>
<surname>Butlin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lindesay</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Viegas</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Avolio</surname>
<given-names>AP</given-names>
</string-name>. <article-title>Pressure dependency of aortic pulse wave velocity in&#x000a0;vivo is not affected by vasoactive substances that alter aortic wall tension ex&#x000a0;vivo</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2015</year>;<volume>308</volume>:<fpage>H1221</fpage>&#x02013;<lpage>H1228</lpage>.<pub-id pub-id-type="pmid">25770242</pub-id></mixed-citation></ref><ref id="jah31337-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jah31337-cit-0046">
<string-name>
<surname>Maki&#x02010;Petaja</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Booth</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Wallace</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McEniery</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>IB</given-names>
</string-name>. <article-title>Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>:<fpage>852</fpage>&#x02013;<lpage>858</lpage>.<pub-id pub-id-type="pmid">17719471</pub-id></mixed-citation></ref><ref id="jah31337-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jah31337-cit-0047">
<string-name>
<surname>Vlachopoulos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dima</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Aznaouridis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Vasiliadou</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ioakeimidis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Aggeli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Toutouza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stefanadis</surname>
<given-names>C</given-names>
</string-name>. <article-title>Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>112</volume>:<fpage>2193</fpage>&#x02013;<lpage>2200</lpage>.<pub-id pub-id-type="pmid">16186422</pub-id></mixed-citation></ref><ref id="jah31337-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jah31337-cit-0048">
<string-name>
<surname>Wallace</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Maki&#x02010;Petaja</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Cheriyan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Davidson</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Cherry</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>McEniery</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Sattar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>IB</given-names>
</string-name>, <string-name>
<surname>Kharbanda</surname>
<given-names>RK</given-names>
</string-name>. <article-title>Simvastatin prevents inflammation&#x02010;induced aortic stiffening and endothelial dysfunction</article-title>. <source>Br J Clin Pharmacol</source>. <year>2010</year>;<volume>70</volume>:<fpage>799</fpage>&#x02013;<lpage>806</lpage>.<pub-id pub-id-type="pmid">21175435</pub-id></mixed-citation></ref></ref-list></back></article>